Abstract:In recent years, the U.S. Food and Drug Administration (FDA) has approved Chimeric Antigen Receptor (CAR)-T cell therapy as a novel approach to treating hematological diseases, including multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia. Using the patient's genetically altered T-cells, this novel strategy precisely targets antigens linked to cancer. Even with the encouraging outcomes of using bi-specific chimeric antigen receptors to stop tumor antigen evasion, difficulties still arise, especially when dealing with solid tumors. There are several challenges because of the intricate interactions among many elements in the tumor microenvironment, such as immunosuppression, hypoxia, decreased T-cell infiltration, elevated reactive oxygen species, and the erratic nature of tumor-associated antigens. This study examines current efforts to find reliable tumor-associated antigens in an attempt to address issues impeding the efficacy of CAR-T treatment. The fundamental objective is to create CAR-T cells that are economical while being adapted to the distinct characteristics of the tumor microenvironment. By means of a comprehensive analysis of the course of the therapy, the study explores its potential therapeutic uses for a range of tumor types, including solid and hematological malignancies. This work not only sheds light on the enormous obstacles to obtaining precision medicine in cancer treatment, but it also advances our knowledge of the promise that the specific therapy has. The presented results open the door for future developments in the field and provide a nuanced viewpoint on the revolutionary role that the treatment has played in the contemporary cancer scene.

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

CAR-T cell therapy: current limitations and potential strategies

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

Current Clinical Application of the CAR-T Cell Therapy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Prospects and challenges for use of CAR T cell therapies in solid tumors

Current progress in CAR-T cell therapy for tumor treatment

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

CAR T cell therapy: Current limitations and advancements in treating solid tumors

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

CAR-T in cancer therapeutics and updates